Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymetrix, Inc.
Wellcome Trust Case Control Consortium and Affymetrix Expand World's Largest Study of Genetic Diseases
August 15th, 2008
Affymetrix, Inc. (Nasdaq:AFFX) announced that the Wellcome Trust of Great Britain has awarded to Affymetrix the second phase of its Case Control Consortium (WTCCC) project, the world's largest-ever study of the genetics behind common diseases. The second phase will analyze the genetic information of 60,000 additional individuals, 30,000 of them with the Affymetrix(R) Genome-Wide Human SNP Array 6.0, plus 6,000 common controls. Over the next year, 14 UK research groups will collaborate with the WTCCC to identify genetic contributions to 14 common diseases and drug responses, including schizophrenia, ulcerative colitis, psychosis, bacteriosis, pre-eclampsia and statin...
Source: Health Business Week (2008-08-15)
|
